Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

What happened

Compass Pathways plc announced it will release third quarter 2026 financial results for the period ended September 30, 2026, on November 3, 2026. Management will host a conference call at 8:00 am ET that day, with a webcast archived for 30 days.

Confirmed

Global impact / market context

The scheduled update gives investors a look at how much cash the company has and how much it is spending on developing COMP360, its investigational psilocybin treatment for depression. Cash available and spending progress matter because drug trials can cost a lot before any revenue arrives.

Analyst inference

Compass is a clinical-stage biotechnology company with no approved product mentioned, so its shares likely trade on trial progress and funding runway rather than sales. COMP360 holds FDA Breakthrough Therapy and UK ILAP designations, which may support faster regulatory review, but approval is not guaranteed.

Analyst inference

What to watch

1. Watch the November 3, 2026 release and 8:00 am ET conference call for third quarter results and recent-development updates, including any news on COMP360 trials for treatment-resistant depression and PTSD. Confirmed
2. Listen for company guidance on trial timelines, enrollment, and spending plans, since delays or higher costs would change how far its cash available stretches before the company needs more funding. Proposed
3. Any share price reaction will likely depend on trial updates and cash runway, which means how long current funds last. Investors may also weigh the cost of raising more money by selling shares or borrowing. Analyst inference

Evidence

• Original source link unavailable